Literature DB >> 28961327

Chronic liver injury alters driver mutation profiles in hepatocellular carcinoma in mice.

Jesse D Riordan1, Charlotte R Feddersen1, Barbara R Tschida2, Pauline J Beckmann2, Vincent W Keng3, Michael A Linden4, Khalid Amin4, Christopher S Stipp5, David A Largaespada2, Adam J Dupuy1.   

Abstract

Most hepatocellular carcinomas (HCCs) develop in a chronically injured liver, yet the extent to which this microenvironment promotes neoplastic transformation or influences selective pressures for genetic drivers of HCC remains unclear. We sought to determine the impact of hepatic injury in an established mouse model of HCC induced by Sleeping Beauty transposon mutagenesis. Chemically induced chronic liver injury dramatically increased tumor penetrance and significantly altered driver mutation profiles, likely reflecting distinct selective pressures. In addition to established human HCC genes and pathways, we identified several injury-associated candidates that represent promising loci for further study. Among them, we found that FIGN is overexpressed in human HCC and promotes hepatocyte invasion. We also validated Gli2's oncogenic potential in vivo, providing direct evidence that Hedgehog signaling can drive liver tumorigenesis in the context of chronic injury. Finally, we show that a subset of injury-associated candidate genes identifies two distinct classes of human HCCs. Further analysis of these two subclasses revealed significant trends among common molecular classification schemes of HCC. The genes and mechanisms identified here provide functional insights into the origin of HCC in a chronic liver damage environment.
CONCLUSION: A chronically damaged liver microenvironment influences the genetic mechanisms that drive hepatocarcinogenesis. (Hepatology 2018;67:924-939).
© 2017 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2018        PMID: 28961327      PMCID: PMC5826818          DOI: 10.1002/hep.29565

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  42 in total

Review 1.  Hedgehog signaling in the liver.

Authors:  Alessia Omenetti; Steve Choi; Gregory Michelotti; Anna Mae Diehl
Journal:  J Hepatol       Date:  2010-10-14       Impact factor: 25.083

2.  Proteomics. Tissue-based map of the human proteome.

Authors:  Mathias Uhlén; Linn Fagerberg; Björn M Hallström; Cecilia Lindskog; Per Oksvold; Adil Mardinoglu; Åsa Sivertsson; Caroline Kampf; Evelina Sjöstedt; Anna Asplund; IngMarie Olsson; Karolina Edlund; Emma Lundberg; Sanjay Navani; Cristina Al-Khalili Szigyarto; Jacob Odeberg; Dijana Djureinovic; Jenny Ottosson Takanen; Sophia Hober; Tove Alm; Per-Henrik Edqvist; Holger Berling; Hanna Tegel; Jan Mulder; Johan Rockberg; Peter Nilsson; Jochen M Schwenk; Marica Hamsten; Kalle von Feilitzen; Mattias Forsberg; Lukas Persson; Fredric Johansson; Martin Zwahlen; Gunnar von Heijne; Jens Nielsen; Fredrik Pontén
Journal:  Science       Date:  2015-01-23       Impact factor: 47.728

3.  Mammalian mutagenesis using a highly mobile somatic Sleeping Beauty transposon system.

Authors:  Adam J Dupuy; Keiko Akagi; David A Largaespada; Neal G Copeland; Nancy A Jenkins
Journal:  Nature       Date:  2005-07-14       Impact factor: 49.962

Review 4.  Risk factors and mechanisms of hepatocarcinogenesis with special emphasis on alcohol and oxidative stress.

Authors:  Helmut K Seitz; Felix Stickel
Journal:  Biol Chem       Date:  2006-04       Impact factor: 3.915

5.  Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair.

Authors:  Chang-Goo Huh; Valentina M Factor; Aránzazu Sánchez; Koichi Uchida; Elizabeth A Conner; Snorri S Thorgeirsson
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-30       Impact factor: 11.205

6.  Adaptive immunity does not strongly suppress spontaneous tumors in a Sleeping Beauty model of cancer.

Authors:  Laura M Rogers; Alicia K Olivier; David K Meyerholz; Adam J Dupuy
Journal:  J Immunol       Date:  2013-03-08       Impact factor: 5.422

Review 7.  Maximizing mouse cancer models.

Authors:  Kristopher K Frese; David A Tuveson
Journal:  Nat Rev Cancer       Date:  2007-09       Impact factor: 60.716

8.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

9.  UpSet: Visualization of Intersecting Sets.

Authors:  Alexander Lex; Nils Gehlenborg; Hendrik Strobelt; Romain Vuillemot; Hanspeter Pfister
Journal:  IEEE Trans Vis Comput Graph       Date:  2014-12       Impact factor: 4.579

10.  Ectopic expression of Zmiz1 induces cutaneous squamous cell malignancies in a mouse model of cancer.

Authors:  Laura M Rogers; Jesse D Riordan; Brian L Swick; David K Meyerholz; Adam J Dupuy
Journal:  J Invest Dermatol       Date:  2013-02-20       Impact factor: 8.551

View more
  11 in total

Review 1.  In vivo functional screening for systems-level integrative cancer genomics.

Authors:  Julia Weber; Christian J Braun; Dieter Saur; Roland Rad
Journal:  Nat Rev Cancer       Date:  2020-07-07       Impact factor: 60.716

Review 2.  Role of taurine, its haloamines and its lncRNA TUG1 in both inflammation and cancer progression. On the road to therapeutics? (Review).

Authors:  Stella Baliou; Anthony M Kyriakopoulos; Demetrios A Spandidos; Vassilios Zoumpourlis
Journal:  Int J Oncol       Date:  2020-07-14       Impact factor: 5.650

Review 3.  Exploring liver cancer biology through functional genetic screens.

Authors:  Cun Wang; Ying Cao; Chen Yang; René Bernards; Wenxin Qin
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-06-23       Impact factor: 46.802

4.  Sesn3 deficiency promotes carcinogen-induced hepatocellular carcinoma via regulation of the hedgehog pathway.

Authors:  Yunjian Liu; Hyeong Geug Kim; Edward Dong; Chuanpeng Dong; Menghao Huang; Yunlong Liu; Suthat Liangpunsakul; Xiaocheng Charlie Dong
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2019-07-24       Impact factor: 5.187

5.  Molecular profiling of nonalcoholic fatty liver disease-associated hepatocellular carcinoma using SB transposon mutagenesis.

Authors:  Takahiro Kodama; Jing Yi; Justin Y Newberg; Jean C Tien; Hao Wu; Milton J Finegold; Michiko Kodama; Zhubo Wei; Takeshi Tamura; Tetsuo Takehara; Randy L Johnson; Nancy A Jenkins; Neal G Copeland
Journal:  Proc Natl Acad Sci U S A       Date:  2018-10-16       Impact factor: 11.205

6.  UPF1 inhibits the hepatocellular carcinoma progression by targeting long non-coding RNA UCA1.

Authors:  Yongli Zhou; Yandong Li; Na Wang; Xiuying Li; Jianyun Zheng; Liqiao Ge
Journal:  Sci Rep       Date:  2019-04-30       Impact factor: 4.379

7.  A simplified transposon mutagenesis method to perform phenotypic forward genetic screens in cultured cells.

Authors:  Charlotte R Feddersen; Lexy S Wadsworth; Eliot Y Zhu; Hayley R Vaughn; Andrew P Voigt; Jesse D Riordan; Adam J Dupuy
Journal:  BMC Genomics       Date:  2019-06-17       Impact factor: 3.969

8.  Fidgetin as a potential prognostic biomarker for hepatocellular carcinoma.

Authors:  Bin Zhou; Jisheng Wang; Jing Gao; Junqing Xie; Yiming Chen
Journal:  Int J Med Sci       Date:  2020-10-16       Impact factor: 3.738

9.  Farnesoid X receptor via Notch1 directs asymmetric cell division of Sox9+ cells to prevent the development of liver cancer in a mouse model.

Authors:  Chenxia Lu; Hanwen Lu; Mi Chen; Junyi Zhang; Dan Qin; Shenghui Liu; Xiaodong Li; Lisheng Zhang
Journal:  Stem Cell Res Ther       Date:  2021-04-12       Impact factor: 6.832

10.  Somatic mutation and expression of BAP1 in hepatocellular carcinoma: an indicator for ferroptosis and immune checkpoint inhibitor therapies.

Authors:  Yu-Chuan Yan; Guang-Xiao Meng; Zi-Niu Ding; Yan-Feng Liu; Zhi-Qiang Chen; Lun-Jie Yan; Ya-Fei Yang; Hui Liu; Chun-Cheng Yang; Zhao-Ru Dong; Jian-Guo Hong; Tao Li
Journal:  J Cancer       Date:  2022-01-01       Impact factor: 4.207

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.